hotspot -WSS

hotspot

author：fashion 2025-10-06 19:27:33 - browse：96427

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： When women are denied an abortion, their children fare worse than peers

leisure time

WSS

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

7 of the most gruesome medical devices in history

Russian special forces kill a gunman who broke into a private house near Moscow

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

focus

hotspot

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Artificial intelligence advances fuel industry trying to preserve loved ones after death

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA authorizes Novavax’s updated Covid

Jerome Adams on the need for new antivirals for Covid

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Medical leaders decry Supreme Court decision on affirmative action

Sana to lay off nearly a third of staff, de

The cancer drug shortage isn’t new — and neither are the solutions

FDA official pushes for dedicated emerging pathogens team

leisure time

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Phenylephrine and the overlooked value of the placebo effect

In new study, freeze

Phenylephrine and the overlooked value of the placebo effect

Artificial intelligence advances fuel industry trying to preserve loved ones after death

Why an extreme heat and wildfire smoke combination can be so dangerous

hotspot

focus

leisure time

Wikipedia